BPC-157 is one of the most studied peptides in the current research literature. It appears in peer-reviewed work spanning tissue repair, gut function, tendon healing, and anti-inflammatory mechanisms — a breadth unusual for a single compound.
This article covers what BPC-157 is, the mechanisms proposed in the research, what the published studies actually show, and what researchers working with it need to know.
Prefer a quick-reference summary? See the BPC-157 Research Brief — mechanism, dosing data, and evidence tiers at a glance.
01 — What Is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a partial sequence of a protein naturally found in gastric juice.
The full designation is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is stable in both acidic and neutral pH environments, which has made it particularly useful in gastrointestinal research contexts where peptides are normally degraded quickly.
BPC-157 does not occur naturally in this exact form — it is a stabilised, isolated partial sequence rather than a complete endogenous protein.
02 — Proposed Mechanisms
The research literature points to several mechanisms by which BPC-157 appears to exert its effects. These are proposed mechanisms based on preclinical studies — the pathways are not fully established in human models.
Angiogenesis and VEGF Upregulation
Multiple studies have observed that BPC-157 promotes the formation of new blood vessels (angiogenesis) through upregulation of vascular endothelial growth factor (VEGF). This is considered a key mechanism in its apparent tissue-repair effects — injured tissue requires vascular support to heal, and BPC-157 appears to accelerate this process in rodent models.
Growth Factor Modulation
BPC-157 has been shown to interact with growth hormone receptor expression and to upregulate several growth factors involved in tissue remodelling, including EGF (epidermal growth factor) and FGF (fibroblast growth factor). This interaction profile is thought to underlie its observed effects on tendon and ligament tissue in animal research.
Nitric Oxide System
Research from the University of Zagreb has documented BPC-157's interaction with the nitric oxide (NO) system. The compound appears to modulate NO synthesis, which has implications for both anti-inflammatory responses and vascular function. Several studies specifically examining this pathway have been published by Sikiric et al. — the research group responsible for a significant portion of the existing BPC-157 literature.
Gut Mucosal Protection
The original research interest in BPC-157 was gastrointestinal. Studies have shown it to exert cytoprotective effects on the gut mucosa in rodent models, including protection against NSAID-induced ulceration and acceleration of fistula healing. The compound's gastric origin and acid stability are directly relevant here.
03 — What the Published Studies Show
The bulk of BPC-157 research comes from preclinical (rodent) models. There are no large-scale human clinical trials at the time of writing. The absence of human trial data is an important limitation that should be factored into any research design.
Tendon and Ligament Healing
Several studies have examined BPC-157 in rodent tendon-transection models. A 2010 paper by Staresinic et al. published in the Journal of Orthopaedic Research found accelerated tendon healing and improved mechanical properties in BPC-157-treated rats compared to controls. Similar findings have been replicated in studies examining Achilles tendon, quadriceps tendon, and ligament repair.
Gastrointestinal Research
The GI literature on BPC-157 is the most extensive. Studies have demonstrated effects on oesophageal-junction lesions, gastric ulcers, colon anastomosis repair, and short bowel syndrome in animal models. Research from the Sikiric group at the University of Zagreb represents the majority of this body of work.
Systemic Anti-Inflammatory Effects
BPC-157 has shown systemic anti-inflammatory effects in rodent models beyond the GI tract — including in muscle injury, inflammatory bowel disease models, and peripheral tissue damage. The proposed mechanism involves both NO modulation and direct downregulation of pro-inflammatory cytokines.
Central Nervous System
More recent research has begun examining BPC-157's interactions with dopamine and serotonin systems in rodent models. Several papers have shown attenuating effects on dopamine-related and opioid-related behavioural disruptions in rats. This is an emerging area of the literature with limited studies relative to the tissue-repair work.
04 — What Is Not Yet Established
The research gaps in BPC-157 are significant and worth stating clearly:
No published human clinical trials — all mechanistic and efficacy data comes from animal models
Optimal research parameters (concentration, reconstitution vehicle, administration route) have not been established in human models
Long-term effects are not studied — all published research examines short to medium-term outcomes in animal subjects
Interaction data with other compounds is limited
Researchers should design protocols with these limitations in mind.
05 — Research Formats Available
BPC-157 is available as a lyophilised powder in sealed research vials. Before use in any research application, it requires reconstitution with bacteriostatic water. A full reconstitution guide is available here →
For storage: unreconstituted vials should be kept refrigerated. Once reconstituted, the research solution should be kept refrigerated and used within 28–30 days.
